Sign in

    QUEST DIAGNOSTICS (DGX)

    Quest Diagnostics Incorporated is a leading provider of diagnostic information services, primarily operating through its Diagnostic Information Services (DIS) and Diagnostic Solutions (DS) segments. The company offers diagnostic insights from laboratory testing, serving a diverse clientele that includes physicians, hospitals, patients, health plans, employers, and government agencies . Additionally, Quest Diagnostics provides risk assessment services for insurers and healthcare information technology solutions for healthcare providers and payers . The company conducts most of its business in the United States but has recently expanded into the Canadian market through acquisitions .

    1. Diagnostic Information Services (DIS) - Provides diagnostic insights from laboratory testing, serving a wide range of customers including physicians, hospitals, patients, health plans, employers, and government agencies. This segment is characterized by a high volume of relatively low-dollar transactions, with revenues recognized primarily upon completion of the testing process .
    2. Diagnostic Solutions (DS) - Offers risk assessment services for insurers and healthcare information technology solutions for healthcare providers and payers. This segment includes solutions under various brands, such as:
      • AmeriPath - Specializes in anatomic pathology services.
      • Dermpath Diagnostics - Focuses on dermatopathology services.
      • ExamOne - Provides risk assessment services for the insurance industry.
      • Quanum - Delivers healthcare information technology solutions .

    You might also like

    NamePositionExternal RolesShort Bio

    James E. Davis

    ExecutiveBoard

    Chairman, CEO, and President

    None

    Joined DGX in 2013. Became CEO on Nov 1, 2022, and Chairman on Apr 1, 2023. Previously held leadership roles at GE and InSightec.

    View Report →

    Catherine T. Doherty

    Executive

    Senior Vice President, Regional Businesses

    None

    Joined DGX in 1990. Held multiple leadership roles, including SVP of Clinical Franchise Solutions and Marketing.

    Karthik Kuppusamy

    Executive

    Senior Vice President, Clinical Solutions

    None

    Joined DGX in 2014. Oversees clinical franchises and pharmaceutical services. Formerly worked at GE Healthcare.

    Mark A. Gardner

    Executive

    Senior Vice President, Molecular Genomics and Oncology

    None

    Joined DGX in October 2022. Previously held leadership roles at Corza Medical, OmniSeq, and Thermo Fisher Scientific.

    Mark E. Delaney

    Executive

    Senior Vice President and Chief Commercial Officer

    None

    Joined DGX in March 2022. Previously held leadership roles at Hill-Rom Holdings and GE Healthcare.

    Michael E. Prevoznik

    Executive

    Senior Vice President and General Counsel

    None

    Joined DGX in 1999. Oversees legal, compliance, and governmental affairs. Previously worked at SmithKline Beecham.

    Patrick Plewman

    Executive

    Senior Vice President, Diagnostics Services

    None

    Joined DGX in 2013. Oversees data-driven analytics and services offerings. Formerly CEO of diaDexus, Inc.

    Sam A. Samad

    Executive

    Executive Vice President and CFO

    None

    Joined DGX in July 2022. Former CFO of Illumina and held senior roles at Cardinal Health and Eli Lilly.

    Denise M. Morrison

    Board

    Director

    Board Member at MetLife, Inc. and Visa, Inc.; Founder of Denise Morrison & Associates

    Joined DGX board in 2019. Former CEO of Campbell Soup Company.

    Gary M. Pfeiffer

    Board

    Director

    None

    Joined DGX board in 2004. Former CFO of DuPont and Secretary of Finance for Delaware.

    Luis A. Diaz, Jr.

    Board

    Director

    Head of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center

    Joined DGX board in 2023. Renowned oncologist known for pioneering work in cancer biomarkers and immunotherapy.

    Robert B. Carter

    Board

    Director

    Board Member at New York Life; Trustee at University of Memphis

    Joined DGX board in May 2024. Former CIO of FedEx Corporation.

    Timothy L. Main

    Board

    Director

    Non-Executive Chairman of WNS (Holdings) Limited

    Joined DGX board in 2014. Extensive experience in capital markets, technology, and corporate governance.

    Timothy M. Ring

    Board

    Lead Independent Director

    Board Member at Becton, Dickinson and Company; Co-founder of TeamFund, Inc.

    Joined DGX board in 2011. Former CEO of C.R. Bard, Inc.

    Tracey C. Doi

    Board

    Director

    Board Member at Pentair plc; Trustee at SunAmerica Series Trust and Season Series Trust

    Joined DGX board in 2021. Former CFO of Toyota Motor North America.

    Vicky B. Gregg

    Board

    Director

    Cofounder of Guidon Partners LLC; Board Member at Acadia Healthcare and Erlanger Health System

    Joined DGX board in 2014. Former CEO of BlueCross BlueShield of Tennessee.

    Wright L. Lassiter III

    Board

    Director

    CEO of CommonSpirit Health; Board Member at Fortive Corporation

    Joined DGX board in 2020. Former CEO of Henry Ford Health System.

    1. With COVID-19 revenues becoming insignificant and impacting growth by only about 50 basis points , how does Quest plan to compensate for this decline and maintain or accelerate organic growth going forward?
    2. Considering that M&A contributed approximately 4% to revenue growth in the quarter and that LifeLabs alone added about $70 million , is the company's growth overly reliant on acquisitions, and what risks do you see in integrating multiple acquisitions, especially in new markets like Canada?
    3. As you expand into new geographies where health systems previously limited your reach , what challenges do you anticipate in gaining market share in these areas, and how might this affect pricing and relationships with local providers?
    4. Given the anticipated increase in interest expense due to recent debt issuance and the plan to retire lower coupon senior notes in 2025 , how will this higher interest burden impact your margins and ability to invest in growth initiatives?
    5. With the dilution from the Haystack MRD acquisition being approximately $0.20 this year and expected improvements next year , can you detail when you expect this investment to become accretive and what is the plan if reimbursement does not meet expectations?

    Research analysts who have asked questions during QUEST DIAGNOSTICS earnings calls.

    Andrew Brackmann

    William Blair & Company, L.L.C.

    4 questions for DGX

    Also covers: ADPT, AWH, BDSX +11 more

    David Westenberg

    Piper Sandler

    4 questions for DGX

    Also covers: ADPT, AKYA, CTKB +12 more

    Elizabeth Anderson

    Evercore ISI

    4 questions for DGX

    Also covers: AGL, ALGN, CAH +22 more

    Jack Meehan

    Nephron Research LLC

    4 questions for DGX

    Also covers: A, AVTR, BIO +17 more

    Kevin Caliendo

    UBS

    4 questions for DGX

    Also covers: AHCO, ALGN, AMWL +14 more

    Michael Cherny

    Leerink Partners

    4 questions for DGX

    Also covers: ACCD, ALGN, CAH +18 more

    Patrick Donnelly

    Citi

    4 questions for DGX

    Also covers: A, AVTR, BIO +20 more

    Pito Chickering

    Deutsche Bank

    4 questions for DGX

    Also covers: ACHC, AHCO, AVAH +17 more

    Erin Wilson Wright

    Morgan Stanley

    3 questions for DGX

    Also covers: ALGN, CAH, CI +14 more

    Ann Hynes

    Mizuho Financial Group

    2 questions for DGX

    Also covers: ARDT, BTSG, CI +17 more

    Luke Sergott

    Barclays

    2 questions for DGX

    Also covers: A, AVTR, BRKR +17 more

    Michael Ryskin

    Bank of America Merrill Lynch

    2 questions for DGX

    Also covers: A, ALGN, AVTR +28 more

    Noah Kava

    Jefferies

    2 questions for DGX

    Aaron

    Bank of America

    1 question for DGX

    Anna Krasinski

    Barclays

    1 question for DGX

    Erin Wright

    Morgan Stanley

    1 question for DGX

    Also covers: ALGN, BTSG, CAH +15 more

    Lisa Gill

    JPMorgan Chase & Co.

    1 question for DGX

    Also covers: AGL, CAH, CI +13 more

    Meghan Holtz

    Jefferies Financial Group Inc.

    1 question for DGX

    Also covers: AHCO, AVAH, EHAB +4 more

    Stephanie Davis

    Barclays

    1 question for DGX

    Also covers: ACCD, CAH, COR +19 more

    Tycho Peterson

    Jefferies

    1 question for DGX

    Also covers: A, AVTR, BIO +21 more
    Program DetailsProgram 1
    Approval DateN/A
    End Date/DurationNo expiration
    Total additional amount$13 billion
    Remaining authorization$1.0 billion
    DetailsAuthorized since May 2003
    YearAmount Due (in millions)Debt TypeInterest Rate% of Total Debt
    2025$600 3.50% Senior Notes 3.50% 9.6% = (600 / 6,251) * 100
    2026$501 Unspecified Not specified 8.0% = (501 / 6,251) * 100
    2027$400 4.60% Senior Notes 4.60% 6.4% = (400 / 6,251) * 100
    2028$1 Unspecified Not specified 0.0% = (1 / 6,251) * 100
    2029$600 Unspecified 4.625% 9.6% = (600 / 6,251) * 100
    2034$850 Unspecified 5.00% 13.6% = (850 / 6,251) * 100
    2037Not specified Unspecified 6.95% N/A
    2040Not specified Unspecified 5.75% N/A
    Thereafter$4,789 Unspecified Not specified 76.6% = (4,789 / 6,251) * 100

    Competitors mentioned in the company's latest 10K filing.

    CompanyDescription

    The largest commercial clinical laboratory competitor in the diagnostic information services industry, competing primarily in the fragmented and highly competitive clinical testing market.

    NameStart DateEnd DateReason for Change
    PricewaterhouseCoopers LLP1995 PresentCurrent auditor

    Notable M&A activity and strategic investments in the past 3 years.

    CompanyYearDetails

    OhioHealth

    2024

    Quest Diagnostics acquired select assets from OhioHealth in an all‐cash deal valued at $200 million, completed on October 13, 2024; the deal expands cost-effective laboratory services with a shift of outreach testing to Quest’s Pittsburgh facility while preserving OhioHealth’s hospital lab operations.

    Three Physician Groups in New York

    2024

    Quest Diagnostics completed an all‐cash transaction for $300 million to acquire the laboratory business of three New York-based physician groups, integrating $243 million in goodwill and $57 million in customer-related intangible assets into its Diagnostic Information Services business to strengthen its regional presence.

    Allina Health

    2024

    The acquisition of select assets from Allina Health’s outreach laboratory services was executed as an all‐cash transaction for $230 million, incorporating $55 million in customer-related intangible assets and $175 million in goodwill, aimed at expanding high-quality lab services in Minnesota and western Wisconsin within Quest’s DIS segment.

    LifeLabs Inc.

    2024

    Quest Diagnostics acquired LifeLabs Inc. for approximately CAN $1.35 billion (around USD $1 billion) by combining cash on hand with proceeds from a $1.85 billion senior notes offering, with the deal expected to enhance diagnostic innovation in Canada while preserving LifeLabs’ brand and management team.

    PathAI Diagnostics

    2024

    Completed on June 10, 2024, this all‐cash acquisition for $100 million involved acquiring select assets including $55 million of tax-deductible goodwill and customer-related intangibles, with efforts to rebrand the Memphis laboratory as Quest’s national AI/digital R&D center to support enhanced pathology services.

    Lenco Diagnostic Laboratories, Inc. (Lenco)

    2024

    In an all‐cash transaction valued at $111 million on February 12, 2024, Quest Diagnostics acquired Lenco Diagnostic Laboratories, integrating $75 million of tax-deductible goodwill and $43 million in customer-related intangible assets, thereby strengthening its Diagnostic Information Services services in New York.

    Haystack Oncology, Inc.

    2023

    Quest Diagnostics’ acquisition of Haystack Oncology, completed on June 20, 2023, was an all‐cash transaction for $392 million (with additional contingent payments up to $150 million based on revenue targets and CMS milestones), aimed at bolstering its capabilities in minimal residual disease testing and liquid biopsy technology with significant goodwill and technology-related intangible assets acquired.

    New York-Presbyterian Laboratory Services

    2023

    The company acquired select assets of New York-Presbyterian’s laboratory services on April 17, 2023, in an all‐cash deal for $275 million, which included $222 million of tax-deductible goodwill and $53 million in customer-related intangible assets, integrating the business into its Diagnostic Information Services segment to expand its health system partnerships.

    Pack Health, LLC

    2022

    Acquired on February 1, 2022, for a net transaction value of $123 million (comprising $105 million cash and $18 million contingent on future revenues), the deal enhanced Quest Diagnostics’ extended care capabilities by integrating a patient engagement platform, with significant goodwill and intangible asset components recognized under the acquisition method.

    Recent press releases and 8-K filings for DGX.

    Quest Diagnostics enters joint venture for Michigan laboratory
    ·$DGX
    New Projects/Investments
    • Corewell Health and Quest Diagnostics have signed a definitive agreement to form Diagnostic Lab of Michigan, LLC, aiming to expand access to quality, affordable lab services statewide.
    • The joint venture will build a 100,000-square-foot state-of-the-art facility at Corewell’s Southfield Center, with operations slated to begin in Q1 2027.
    • Ownership will be split 51% to Quest and 49% to Corewell Health, aligning with Quest’s growth and profitability criteria; financial terms were not disclosed.
    • Quest will manage its Collaborative Lab Solutions for Corewell’s 21 hospital labs, with supply chain and reference agreements starting in late 2025 and lab management services in 2026.
    Aug 26, 2025, 1:00 PM
    Quest Diagnostics receives FDA Breakthrough Device Designation for Haystack MRD test
    ·$DGX
    Product Launch
    • Quest Diagnostics secures Breakthrough Device Designation from FDA for its Haystack MRD test to identify MRD-positive patients with stage II colorectal cancer post-surgery.
    • The designation aims to expedite development, assessment and review for premarket approval, 510(k) clearance and De Novo marketing under FDA’s Breakthrough Devices Program.
    • Quest introduced a clinical laboratory-developed version of Haystack MRD in late 2024 and is broadening access for oncologists and pharmaceutical partners.
    • Haystack MRD, a ctDNA-based liquid biopsy test, detects residual or recurrent solid-tumor cancer and is available for clinical use and investigational trials in the U.S., Germany and Finland.
    Aug 25, 2025, 12:52 PM
    Quest Diagnostics completes acquisition of Spectra Laboratories assets
    ·$DGX
    M&A
    • Quest Diagnostics closed the acquisition of select clinical testing assets from Fresenius Medical Care’s Spectra Laboratories, with additional dialysis-related water testing assets expected by end-2025.
    • Signed a laboratory services agreement to begin providing comprehensive dialysis-related testing for Fresenius-operated clinics serving approximately 200,000 patients annually, with full transition by early 2026.
    • The deal is expected to reduce transport times, optimize lab network utilization, and strengthen Quest’s leadership in chronic kidney disease diagnostics.
    Aug 5, 2025, 12:33 PM
    Quest Diagnostics raises 2025 guidance after strong Q2 performance
    ·$DGX
    Earnings
    Guidance Update
    M&A
    • Quest Diagnostics reported Q2 2025 revenue of $2.76 B (up 15.2% YoY), including 5.2% organic growth.
    • Adjusted EPS was $2.62 (up 11.5% YoY), and adjusted operating margin expanded to 16.9% of revenues (vs. 16.6% last year).
    • The company raised its full-year 2025 guidance to $10.80 B–$10.92 B in revenues and $9.63–$9.83 in adjusted EPS.
    • Growth drivers included organic demand for advanced diagnostics, accretive acquisitions (e.g., LifeLabs), and productivity gains from automation and AI.
    Jul 22, 2025, 4:31 PM
    Quest Diagnostics Updates at William Blair Conference
    ·$DGX
    Guidance Update
    M&A
    New Projects/Investments
    • Quest Diagnostics highlighted its strong market position in the clinical lab space, emphasizing widespread patient coverage and robust operational scale, including over 350,000 daily patients and serving more than 50% of U.S. hospitals and physicians.
    • The presentation detailed strategic initiatives such as network expansion, productivity improvements, and innovations in high-value tests like the new Alzheimer’s blood-based diagnostic and oncology advancements.
    • The company reaffirmed its long-term guidance of 4-5% revenue CAGR and 7-9% EPS CAGR, alongside updates on significant investments in M&A (including its recent LifeLabs acquisition) and consumer direct channels.
    Jun 4, 2025, 2:21 AM
    Quest Diagnostics Reports Strong Q1 2025 Earnings and Reaffirms Full-Year Guidance
    ·$DGX
    Earnings
    Guidance Update
    M&A
    Revenue Acceleration/Inflection
    • Q1 2025 revenue reached $2.65 billion, up 12.1% year-over-year, reflecting robust quarterly performance .
    • Reported diluted EPS of $1.94 (up 12.8% YoY) and adjusted EPS of $2.21, underscoring strong operational performance .
    • Reaffirmed full-year guidance with expected revenues between $10.7B and $10.85B and EPS guidance of reported diluted EPS between $8.62 and $8.87 plus adjusted diluted EPS between $9.55 and $9.80 .
    • Strategic investments in advanced diagnostics—including tests like PFAS forever chemicals, Haystack MRD, and an AD-Detect panel for Alzheimer’s—are fueling growth .
    • Operational enhancements through automation, robotics, and AI are boosting quality and productivity .
    • A robust M&A pipeline complemented by strategic acquisitions, enterprise account growth, and favorable regulatory developments (e.g., the court decision on FDA LDT rule) is driving further expansion .
    Apr 22, 2025, 12:31 PM
    Quest Diagnostics Launches New AD-Detect Blood Test
    ·$DGX
    Product Launch
    New Projects/Investments
    • Quest Diagnostics announced the launch of its new AD-Detect™ blood test, which confirms Alzheimer’s pathology in patients with mild cognitive impairment or dementia using proprietary tandem mass spectrometry and immunoassay techniques.
    • The test demonstrated over 90% sensitivity and specificity with positive and negative predictive values of 89% in a real-world heterogeneous population, offering a less invasive and more affordable alternative to PET imaging and lumbar puncture.
    • The expansive network of nearly 8,000 patient access points supports broad adoption, excluding only New York where clinical approval is pending.
    Apr 9, 2025, 11:53 AM
    Quest Diagnostics 2025 Investor Day Emphasizes Innovation and Strategic Growth
    ·$DGX
    New Projects/Investments
    M&A
    Guidance Update
    • Investor Day Overview: The event detailed Quest Diagnostics’ commitment to sustainable growth by addressing market trends such as rising obesity and evolving disease diagnostic needs, setting the stage for strategic operational improvements.
    • Diagnostic Innovation: Executives highlighted investments in advanced clinical solutions, including enhanced blood-based testing, AI-driven digital pathology, and automation initiatives designed to drive above‐average growth in key clinical areas.
    • Operational Transformation: The company is modernizing its order-to-cash process through Project Nova and expects to achieve 3% annual productivity savings by standardizing, simplifying, and digitizing its processes, further enhancing customer and employee experience.
    • Financial and M&A Outlook: With reaffirmed 2025 guidance of approximately $10.78 billion in revenue and $9.68 EPS, Quest Diagnostics also outlined long-term targets of 4-5% revenue CAGR and 7-9% adjusted EPS CAGR, supported by disciplined M&A activities and strategic regional consolidations.
    Mar 19, 2025, 1:01 PM
    Quest Diagnostics Outlines Long-Term Growth Strategy at Investor Day 2025
    ·$DGX
    Revenue Acceleration/Inflection
    M&A
    New Projects/Investments
    • Growth Outlook: The company presented a long-term strategy targeting 4%-5% revenue CAGR and 7%-9% adjusted EPS CAGR beyond 2025, underpinned by operational improvements and investments in advanced diagnostics.
    • Expansion and Acquisitions: Quest highlighted the completion of several key acquisitions in 2024 expected to generate approximately $1 billion in annualized revenue, enhancing its reach in the hospital and physician channels.
    • Innovative Market Positioning: The presentation emphasized leveraging technological innovations such as AI and automation to capitalize on strong market trends in both the US and Canadian lab sectors, driving above-market, double-digit growth in key clinical areas.
    Mar 19, 2025, 1:00 PM
    Quest Diagnostics Outlines Strategic Growth Priorities at 2025 Investor Day
    ·$DGX
    Guidance Update
    New Projects/Investments
    • Long-term growth outlook reaffirmed: The company projects 4-5% revenue CAGR and 7-9% adjusted EPS CAGR beyond 2025, driven by strategic investments in advanced diagnostics, automation, and IT modernization initiatives such as Project Nova.
    • Full year 2025 guidance confirmed: Net revenues are expected to range between $10.70 billion and $10.85 billion, although first-quarter headwinds from adverse weather may impact revenue by approximately $25 million and EPS by $0.10.
    • Focused expansion across key channels: Quest Diagnostics is actively enhancing its presence in the physician and hospital channels with initiatives aimed at increasing market access and operational productivity.
    Mar 19, 2025, 11:52 AM